AS­CO17: As­traZeneca pumps up ex­pec­ta­tions on near-term can­cer drug wins, look­ing to shed a rep for fail­ure

CHICA­GO — As­traZeneca’s R&D team ar­rived at AS­CO on a crit­i­cal mis­sion.

With its lead­ing PARP in­hibitor outscor­ing chemo in treat­ing breast can­cer,  mak­ing the spot­light round on Sun­day, As­traZeneca was able to of­fer some fresh, sol­id ev­i­dence of its con­tin­u­ing progress on the all-im­por­tant can­cer front. And with sev­er­al key cat­a­lysts lined up over the sum­mer, ex­ecs want­ed to send a clear mes­sage that this can­cer drug roll they’re on is just be­gin­ning.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER